Search research articles
Contact Us
Filters
Showing results (11-20 of 25) with videos related to
Page
of 3
Sort By:
Molecular Cancer Therapeutics
|
March 18, 2016
An Unbiased Oncology Compound Screen to Identify Novel Combination Strategies
Jennifer O'Neil, Yair Benita, Igor Feldman, et al.
Cancer Immunology Research
|
December 23, 2020
ONCR-177, an Oncolytic HSV-1 Designed to Potently Activate Systemic Antitumor Immunity
Brian B Haines, Agnieszka Denslow, Peter Grzesik, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 17, 2014
Combination of the mTOR inhibitor ridaforolimus and the anti-IGF1R monoclonal antibody dalotuzumab: preclinical characterization and phase I clinical trial
Serena Di Cosimo, Sriram Sathyanarayanan, Johanna C Bendell, et al.
Translational Oncology
|
January 17, 2013
Evidence of mTOR Activation by an AKT-Independent Mechanism Provides Support for the Combined Treatment of PTEN-Deficient Prostate Tumors with mTOR and AKT Inhibitors
Weisheng Zhang, Brian B Haines, Clay Efferson, et al.
Molecular Cancer Therapeutics
|
June 4, 2016
High Levels of Expression of P-glycoprotein/Multidrug Resistance Protein Result in Resistance to Vintafolide
Amy D Guertin, Jennifer O'Neil, Alexander Stoeck, et al.
Molecular Therapy Oncolytics
|
September 21, 2020
Design of an Interferon-Resistant Oncolytic HSV-1 Incorporating Redundant Safety Modalities for Improved Tolerability
Edward M Kennedy, Terry Farkaly, Peter Grzesik, et al.
Bioorganic & Medicinal Chemistry Letters
|
March 10, 2009
Exploring the pharmacokinetic properties of phosphorus-containing selective HDAC 1 and 2 inhibitors (SHI-1:2)
Richard W Heidebrecht, Melissa Chenard, Joshua Close, et al.
Cell Reports Methods
|
June 1, 2026
Temporal control of sgRNA library activation unlocks large-scale in vivo CRISPR screens
Silvia Fenoglio, Yi Yu, James Tepper, et al.
Cancer Discovery
|
August 9, 2014
Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma
Alexander Stoeck, Serguei Lejnine, Andrew Truong, et al.
Cancer Research
|
June 10, 2026
TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Anti-Tumor Immunity and Immunotherapy Efficacy
Alvin Ziying Lu, Brian B Haines, Wenhai Zhang, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 25) with videos related to
Sort By:
Page
of 3
Molecular Cancer Therapeutics
|
March 18, 2016
An Unbiased Oncology Compound Screen to Identify Novel Combination Strategies
Jennifer O'Neil, Yair Benita, Igor Feldman, et al.
Cancer Immunology Research
|
December 23, 2020
ONCR-177, an Oncolytic HSV-1 Designed to Potently Activate Systemic Antitumor Immunity
Brian B Haines, Agnieszka Denslow, Peter Grzesik, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 17, 2014
Combination of the mTOR inhibitor ridaforolimus and the anti-IGF1R monoclonal antibody dalotuzumab: preclinical characterization and phase I clinical trial
Serena Di Cosimo, Sriram Sathyanarayanan, Johanna C Bendell, et al.
Translational Oncology
|
January 17, 2013
Evidence of mTOR Activation by an AKT-Independent Mechanism Provides Support for the Combined Treatment of PTEN-Deficient Prostate Tumors with mTOR and AKT Inhibitors
Weisheng Zhang, Brian B Haines, Clay Efferson, et al.
Molecular Cancer Therapeutics
|
June 4, 2016
High Levels of Expression of P-glycoprotein/Multidrug Resistance Protein Result in Resistance to Vintafolide
Amy D Guertin, Jennifer O'Neil, Alexander Stoeck, et al.
Molecular Therapy Oncolytics
|
September 21, 2020
Design of an Interferon-Resistant Oncolytic HSV-1 Incorporating Redundant Safety Modalities for Improved Tolerability
Edward M Kennedy, Terry Farkaly, Peter Grzesik, et al.
Bioorganic & Medicinal Chemistry Letters
|
March 10, 2009
Exploring the pharmacokinetic properties of phosphorus-containing selective HDAC 1 and 2 inhibitors (SHI-1:2)
Richard W Heidebrecht, Melissa Chenard, Joshua Close, et al.
Cell Reports Methods
|
June 1, 2026
Temporal control of sgRNA library activation unlocks large-scale in vivo CRISPR screens
Silvia Fenoglio, Yi Yu, James Tepper, et al.
Cancer Discovery
|
August 9, 2014
Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma
Alexander Stoeck, Serguei Lejnine, Andrew Truong, et al.
Cancer Research
|
June 10, 2026
TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Anti-Tumor Immunity and Immunotherapy Efficacy
Alvin Ziying Lu, Brian B Haines, Wenhai Zhang, et al.
Page
of 3